Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: DaveAu who wrote (5889)	11/27/2000 11:07:43 AM
From: Ron Nairn	Respond to of 14101

It been stated in prior posts that Rebecca had the UK in her pocket when she set the November 30 forecast and that she was holding out for better labeling authorization. A review of the press release does not clearly state she has it but alludes to Pensaid's superiority... Although there are a number of topical NSAIDs approved in the UK, they are generally not well regarded as they lack strong efficacy data. In contrast, PENNSAID(R) has demonstrated efficacy using the same international standards used to establish the efficacy of oral NSAIDs, including the new COX- 2 selective NSAIDs. Mrs. Keeler noted that "the UK decision validates the safety and efficacy of PENNSAID and we expect its first commercial launch to be an important source of revenue for Dimethaid in 2001 and beyond." Do we assume yes/no? Rondo

To: DaveAu who wrote (5889)	11/27/2000 11:10:02 AM
From: john.d	Read Replies (1) \| Respond to of 14101

Dave, <I can't get any work done today> Well, I'm on holidays and so far It's been pretty exciting. good thing go for my company that I'm not at work, since I wouldn't be getting anything done either. Who knows if DMX takes off as we all hope and expect maybe I will not need to go back to work<GGG> John P.S I hope that Peter Block is able to participate in some way after all the the work that he did.

To: DaveAu who wrote (5889)	11/27/2000 11:39:40 AM
From: Cal Gary	Respond to of 14101

Hi Bluejay, I can't get any work done today. I've been getting calls (and making calls) since before the market opened. Many friends are sitting in Monday morning meetings, they don't even know of the announcement yet. The few friends that I did call, they have since called back blaming me "they can't get any work done, now." Deja vu. Approaching 1/2 million shares, and still available at 5.50. Updated "attempt at a" list 1 UK Partner announcement with $$ 2 HSBC analyst report release (no sign of HSBC buying today, yet) 3 Inaugural announcement of product shipment out of warehouse 4 get another 5%-10% of OXO 5 More analyst coverage 6 Other European marketing license and partners 7 Q2, then Q3 to give us indication of how rich the UK deal was 8 HPC 9 FDA 10 JnJ with $$$$ Perhaps someone can draw up a new short term list of what to expect. I'm just about finished eating crow from my last list. EDIT Pennsaid, Works and Works Well